Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 18/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29947339 | 0.88 | GLP1R (0.47) | GLP1RPDE10A | |
| SCHEMBL22391958 | 0.88 | GLP1R (0.47) | GLP1RPDE10A | |
| SCHEMBL26914039 | 0.86 | GLP1R (0.49) | GLP1R | |
| SCHEMBL28934327 | 0.86 | GLP1R (0.42) | GLP1RPDE10AHTR1ACYP2C8KCNH2 | |
| SCHEMBL29150010 | 0.86 | GLP1R (0.49) | GLP1RPDE10AHTR1ACYP2C8KCNH2 | |
| SCHEMBL29555077 | 0.84 | GLP1R (0.47) | GLP1RPDE10A | |
| SCHEMBL25222520 | 0.83 | KCNH2 (0.39) | GLP1RPDE10AHTR1ACYP2C8KCNH2 | |
| SCHEMBL29554872 | 0.83 | GLP1R (0.40) | GLP1R | |
| SCHEMBL30372891 | 0.82 | CTSB (0.40) | GLP1RPDE10AKCNH2 | |
| SCHEMBL29554814 | 0.81 | GLP1R (0.39) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590081-B2 | Fused imidazole derivatives, preparation method and medicinal use thereof | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2026-03-31 | — | — | US | disclosed |
| US-20230126875-A1 | FUSED IMIDAZOLE DERIVATIVES, PREPARATION METHOD AND MEDICINAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4130003-A1 | FUSED IMIDAZOLE DERIVATIVES, PREPARATION METHOD AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590081-B2 | Fused imidazole derivatives, preparation method and medicinal use thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885PDE10A 373/4885HTR1A 205/4885 |
| US-20230126875-A1 | FUSED IMIDAZOLE DERIVATIVES, PREPARATION METHOD AND MEDICINAL USE THEREOF | GLP1R, GIPR, GPR119 | GLP1R 1/4885PDE10A 122/4885HTR1A 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.